A COMPARATIVE STUDY ON CIPLA AND CADILA

PHARMACEUTICALS WITH REFERENCE TO BOMBAY

MEDICALS, ARUPPUKOTTAI TOWN.

Project report submitted in partial fulfillment of the requirements for the awards of
the Degree of
BACHELOR OF BUSINESS ADMINISTRATION
OF
MADURAI KAMARAJ UNIVERSITY
MADURAI

Submitted by

MAHENDRAN.M

(Reg.No: 922619631016)

Under the guidance of

DR. V. SEEMA, MBA, Ph.D.,

ASSISTANT PROFESSOR

DEVANGAR ARTS COLLEGE

ARUPPUKOTTAI TOWN

MAY–2023
 BONAFIDE CERTIFICATE

This is to certify that Mr. MAHENDRAN.M (Reg.No:922619631016) is a bonafide

student of Devangar Arts College, Aruppukottai Town, has successfully completed the
project work titled on “A COMPARATIVE STUDY ON CIPLA AND CADILA
PHARMACEUTICALS WITH REFERENCE TO BOMBAY MEDICALS,
ARUPPUKOTTAI TOWN” in partial fulfillment of the requirement of Bachelor Of
Business Administration (MBA) Program for the academic year 2019-2021.

PROJECT GUIDE PRINCIPAL & DIRECTOR

Project report was submitted and Viva-Voce held on at

Devangar Arts College.

INTERNAL EXAMINER EXTERNAL EXAMINER

 DECLARATION

I, MAHENDRAN.M (Reg.No: 922619631016) hereby declare that the project report

entitled, “A COMPARATIVE STUDY ON CIPLA AND CADILA
PHARMACEUTICALS WITH REFERENCE TO BOMBAY MEDICALS,
ARUPPUKOTTAI TOWN” submitted by me to the Madurai Kamaraj University,
Chennai, in partial fulfillment of the requirement for the award of degree of
BACHELOR OF BUSINESS ADMINISTRATION under the guidance of DR. V.
SEEMA, MBA, Ph.D., is my original work.

PLACE: ARUPPUKOTTAI TOWN MAHENDRAN.M

DATE: (Register No: 922619631016)
 ACKNOWLEDGEMENT

I am grateful to Dr.T.DEVANGAR ARTS COLLEGEARAGHAVAN, M.Sc, MCA,

MBA (Ind), MBA (USA),
Ph.D., Chairman, Devangar Arts College Institute of Management, Aruppukottai
Town for providing inspiration and moral support during the course of MBA.

I would like to thank Dr.Ir.VADIVU DEVANGAR ARTS

COLLEGEARAGHAVAN, BE, MS(NL), MBA, (Ph.D)., Trustee, Devangar Arts
College Institute of Management, Aruppukottai Town for giving the opportunity to
continue my MBA studies and for its financial support.

I am indebted to Dr.N.SWARNALATHA, M.B.A., M.Phil., Ph.D., Principal and

Director, Devangar Arts College Institute of Management, Aruppukottai Town, for his
support during the entire course of this project work.

It is with great appreciation and gratitude towards my guide DR. V. SEEMA, MBA,
Ph.D., Assistant Professor, Devangar Arts College Institute of Management,
Aruppukottai Town, for helpful guidance, valuable support, timely feedback and
comments for my documentations.

I wish to express my sincere thanks to Mr. P. Alagu Malai, Bombay medicals,

Aruppukottai Town, and all the personnel in for their constant encouragement and
support at all stages of project work.

I would like to be grateful to my God Almighty for giving me health and strength to
continue and finish this study.

Finally, I wish to thank all the faculty members, friends, and my parents for their
continuous help to complete this project successfully on time.
 TABLE OF CONTENTS

CHAPTER TITLE PAGE

NO. NO.
1.1 INTRODUCTION 1–7
1.2 STATEMENT OF THE PROBLEM 8
1.3 OBJECTIVES OF THE STUDY 9
01 1.4 SCOPE OF THE STUDY 9
1.5 INDUSTRY PROFILE 10 – 12
1.6 COMPANY PROFILE 13 – 15
1.7 LIMITATIONS OF THE STUDY 16
1.8 CHAPTER SCHEME 17
02 2.1 REVIEW OF LITERATURE 18 – 19
2.2 RESEARCH GAP 20
3.1 RESEARCH METHODOLOGY 21
3.2 SAMPLING 21
03 3.3 PERIOD COVER BY THE STUDY 22
3.4 SOURCES OF DATA 22
3.5 TOOLS USED FOR THE STUDY 22
3.6 HYPOTHESIS OF THE STUDY 23
4.1 DATA ANALYSIS & 24 – 46
04 INTERPRETATION
4.2 TESTING OF HYPOTHESIS 47
5.1 FINDINGS 48 – 49
05 5.2 SUGGESTIONS 50
5.3 CONCLUSION 51
ANNEXURE 52 – 54
REFERENCES 55 – 56
 LIST OF TABLES

TABLE PARTICULARS PAGE

NO: NO.
Age of the respondents 24
4.1.1
4.1.2 Gender of the respondents 25

4.1.3 Locality of the respondents 26

4.1.4 Marital status of the respondents 27

4.1.5 Disease rapidly cured by cipla 28

4.1.6 Disease rapidly cured by cadila 29

4.1.7 Availability of cipla medicine & drugs 30

4.1.8 Availability of cadila medicine & drugs 31

4.1.9 Bought medicines on online 32

4.1.10 Peoples/patients mostly use cipla medicines 33

4.1.11 Peoples/patients mostly use cadila medicines 34

4.1.12 Brand suggested by MD,DM doctors mostly 35

4.1.13 Brand suggested by MBBS doctors mostly 36

4.1.14 Brand suggested by MBBS DLO doctors mostly 37

4.1.15 Discount from distributors gives for cipla medicines & drugs 38

4.1.16 Discount from distributors gives for cadila medicines & drugs 39

4.1.17 Advertisement is for cadila for sales promotion 40

4.1.18 Advertisement is for cipla for sales promotion 41

4.1.19 Nominal level for comaprison of cipla & cadila 42 - 44

4.1.20 Doctors disciplines who suggests cipla mostly 45

4.1.21 Doctors disciplines who suggests cadila mostly 46

 LIST OF CHARTS

CHART PARTICULARS PAGE

NO: NO.
Age of the respondents 24
4.1.1
4.1.2 Gender of the respondents 25
4.1.3 Locality of the respondents 26
4.1.4 Marital status of the respondents 27
4.1.5 Disease rapidly cured by cipla 28
4.1.6 Disease rapidly cured by cadila 29
4.1.7 Availability of cipla medicine & drugs 30
4.1.8 Availability of cadila medicine & drugs 31
4.1.9 Bought medicines on online 32
4.1.10 Peoples/patients mostly use cipla medicines 33
4.1.11 Peoples/patients mostly use cadila medicines 34
4.1.12 Brand suggested by MD,DM doctors mostly 35
4.1.13 Brand suggested by MBBS doctors mostly 36
4.1.14 Brand suggested by MBBS DLO doctors mostly 37
Discount from distributors gives for cipla medicines &
4.1.15 drugs 38
Discount from distributors gives for cadila medicines &
4.1.16 drugs 39
4.1.17 Advertisement is for cadila for sales promotion 40
4.1.18 Advertisement is for cipla for sales promotion 41
4.1.19 Nominal level for comaprison of cipla & cadila 42 - 44
4.1.20 Doctors disciplines who suggests cipla mostly 45
4.1.21 Doctors disciplines who suggests cadila mostly 46
 ABSTRACT

The study examined the comparativeness between the pharmaceuticals of cipla

& cadila, leading pharmaceutical companies in India. The factors which govern those
comparativeness like preferences of customers, suggestions or prescription by doctors,
economically accessibility, distributors contribution, health accountability,
advertisement, availability, sales turnover, etc. The study data collected from the
employees of pharmacy and doctors of various disciplines through mailed
questionnaires with help of google form. The data was analysis with help of MS-Excel
& SPSS. The simple Column and Bar charts and tables were used to present the
analysis based on tool called Percentage Analysis and Correlation. The response was
collected from the 120 samples from various disciplines of employees. The sampling
techniques used for this study was convenient sampling method for non – probability
samples. This study concludes that the results of immensely compatibility between
those pharmaceuticals in the selected region.

Key Words: Comparative study, Pharmaceuticals, medicines & drugs.

 CHAPTER - I

1.1. INTRODUCTION
Looking to the features of Indian population like huge size, majority of lower
income group, lees personal budget for medical treatment, adverse climatic condition
etc., it is very important that they get quality medical treatment and medical products,
not only that but affordable prices. Indian pharmaceutical industry has not only
performed exceedingly well in terms of production, domestic R&D, value addition,
regional spread and diversification but also provided employment for millions and also
in contributing to better health for millions of people by being largely cost-effective
and, hence providing medicines at affordable price. Moreover, the Indian
pharmaceutical industries has been able to exports its products to a number of countries
where Indian medicines have been popular due both to their low cost and effectiveness.
Thus Indian pharmaceutical industry is rapidly globalizing making it important for
Indian pharmaceutical companies to ensure their practices match those of the best
pharmaceutical industry in the world. Therefore the pharmaceutical companies are
significantly important compared to other companies.

The majority of global pharmaceutical sales originated in the “Triad” (US,

European Union and Japan), and together they are accounting for over 80% of the
global market. At the regional level US, is the major pharmaceutical market accounting
for around 45% of global pharmaceutical sales, followed by Europe (24%) and Japan
(11%).

The Indian pharmaceutical market is third largest in terms of volume and

thirteen largest in terms of value. The market is dominated majorly by branded generics
which constitute nearly 70 to 80 per cent of the market. Technologically strong and
totally self- reliant, the pharmaceutical industry in India has low costs of production,
low R&D costs, innovative scientific manpower, strength of national laboratories and
an increasing balance of trade. The Indian pharmaceutical Industry, with its rich
scientific talents and research capabilities, supported by Intellectual Property Protection
regime is well set to take on the international market.

The history of modern Indian pharmaceutical industry (IPI) dates back to the
early twentieth century when increased nationalism gave rise to greater interest in

1
science, including pharmaceuticals. The foundation to two firms, which are still in

2
existence today, marks the start of the modern pharmaceutical industry. One is Bengal
Chemical and Pharmaceutical Work (BCPW) Ltd. set up in Kolkata by Acharya PC
Ray in 1901. The other is Alembic Chemical Works Co. Ltd. in Vadodara by TK
Grajjar,Rajmitra and BD Amin in 1907. Both the companies began an important shift
from traditional methods to a more scientific approach to the discovery, development
and manufacture of pharmaceuticals.

At the early stage of development, Indian pharmaceutical companies relied

heavily on foreign companies for their bulk drug requirements. The development of the
IPI can be divided into three phases:

1) Indian Pharmaceutical Industry from 1900 to 1970.

2) Indian Pharmaceutical Industry from 1970 to 1990.

3) Indian Pharmaceutical Industry after 1995: Post TRIPs Period.

MAJOR PLAYERS IN INDIAN PHARMACEUTICAL SECTOR:

Indian pharmaceutical industry companies can broadly be classified as domestic
companies and foreign companies (MNCs). Some of the major players include
GlaxoSmithKline, Cipla, Dr. Reddy’s Laboratories, Ranbaxy, Pfizer etc. Financial year
2013 was challenging on the domestic front and witnessed sluggish growth owing to
acute competition from unlisted players and so on.

TYPES OF DRUG SYSTEMS IN INDIA:

Ancient civilization allowed India to develop various kinds of medical and
pharmaceutical systems. In addition to allopathic system, the following type of
medicine systems are also used by Indians:

a) Ayurveda:
Ayurveda translates as the science of life. It encompasses fundamentals and
philosophies about the world and life, disease and medicines. The knowledge of
Ayurveda is compiled in Charak Samhita and Sushuta Samhita. The curative
treatment lies in drugs, diet and general mode of life.

3
b) Siddha:
The Siddha system is one on the oldest Indian systems of medicines. Siddha
means achievement. Siddhas were saintly figures who achieved healing through the
practice of yoga. The Siddha system does not look merely at a disease but takes into
account a patient's age, sex, race, habits, environment, diet, physiological
constitution and so forth.

c) Unani:
The Unani system originated in Greece and progressed to India during
medieval period. The system is based on humeral theory, i.e. the presence of blood,
phlegm, yellow bile and black bile. A person's temperament is accordingly
expressed as sanguine, phlegmatic, choleric or melancholic. Drugs derived from
plant, metal, mineral and animal origins are used in this system.

d) Homeopathy:
This science flourished in Germany during 17th and 18th Centuries. In India
this science is commonly used to treat disease. It normally uses a single medicine
and dosage is minimal just enough to cure the disease.

e) Yoga and naturopathy:

This science is way of life. In naturopathy, one applies laws of nature. It
advocates proper attention to eating and living habits. It also involves hydro
therapy, mud packs, baths, massage and so forth.

4
CONCEPTUAL DEFINITION OF COMPARTIVE STUDY:
Comparative Study analyzes and compares two or more objects or ideas.
Comparative studies are the studies to demonstrate ability to examine, compare and
contrast subjects or ideas. Comparative study shows how two subjects are similar or
shows how two subjects are different. When the practice of comparative study began is
a matter of debate. Karl Deutsch has suggested we have been using this form of
investigation for over 2,000 years. Comparing things is essential to basic scientific and
philosophic inquiry, which has been done for a long time. Most authors are more
conservative in their estimate of how long comparative study has been with us. It is
largely an empty debate over the definition of the tradition with those questioning
whether comparing things counts as comparative study research. Textbooks on this
form of study were beginning to appear by the 1880s, but its rise to extreme popularity
began after World War II. There are numerous reasons that comparative study has
come to take a place of honor in the toolbox of the social scientist.

Globalization has been a major factor, increasing the desire and possibility for
educational exchanges and intellectual curiosity about other cultures. Information
technology has enabled greater production of quantitative data for comparison, and
international communications technology has facilitated this information to be easily
spread. In Comparative study we compare and contrast two or more things.

Comparative study is used to determine and quantify relationships between two

or more variables by observing different groups that either by choice or circumstances
is exposed to different treatments.

Comparative study looks at two or more similar groups, individuals, or

conditions by comparing them. This comparison often focuses on a few specific
characteristics. Comparative study plays a central role in concept formation by bringing
into focus suggestive similarities and contrasts among cases/subjects. It sharpens our
power of description. Comparative study is also used in testing hypotheses, and it can
contribute to the inductive discovery of new hypotheses and to theory building.
Comparative study is a type of research that is necessary to achieve higher studies. The
comparative study explains what the relation is between the two subjects. Are the two
subjects contradictory,
5
are they extensions of each other? This type of study compares two or more things that
have significant differences. If we compare two books, two historical figures or two
politicians, we should analyze them and highlights the significant differences with
multiple perspectives in order to draw conclusions based on research. We will become
a better researcher when we look at multiple sides of our subject matter. When we are
able to explain our differences, we strengthen our position.
Comparative studies allow us to focus on our research and primary arguments.
Comparative study is the act of comparing two or more things with a view to
discovering something about one or all of the things being compared. Comparative
study helps to define the organization structure of the subjects as well as give the
differential points between the subjects matter. In comparative study we attempt to
identify a cause effect relationship between two or more groups. Comparative studies
involve comparison in contrast to correlation research which looks at relationship.
Comparative study involves understanding, studying and explaining every aspects or
events. Its purpose is to arrive at some conclusions concerning past occurrences that
may help to anticipate or explain present or future events. Comparative study focuses
on the differences between the two subjects and clearly defines the comparative nature
of the subjects. So it is clear that is comparative study we compare two things or
finding their differences or both. We should decide whether the two things that are
being compared are more similar or more different. For example when comparing two
countries, we might look what different kinds of governments they each have, how the
cultures may differ.

There are certainly methods far more common than others is comparative
studies. Qualitative analysis is much more frequently pursued than quantitative, and
this is seen in the majority of comparative studies which use quantitative data. The
general criteria of comparing things are the same for comparative study as it is in our
everyday practice of comparison. Like cases/subjects are treated alike, and different
cases/subjects are treated differently; the extent of difference determines how
differently cases are to be treated. A good example of this is the common research
program that looks for differences between two or more behaviors of social,
economical, cultural, ethical, political and geographical systems, and then looks at
these differences in relation to some other variable coexisting in those societies to see if
it is related.

6
 According to Esping‐Anderson’s research, comparative study can take many
forms. Two important key factors are space and time. Spatially cross‐national
comparisons are by far the most common, although comparisons within countries,
contrasting different areas, cultures and governments also subsist and are very
constructive.

The comparative study also involves comparing different time frames. The
comparative study helps the researcher to ascend from the initial level of exploratory
case studies to a more advanced level of general theoretical models, invariance’s, such
as causality or evolution. The comparative study is simple designs, objects are
specimens or cases which are similar in some respects but they differ in some respects.
These differences become the focus of examination. The goal is to find out why the
cases are different to reveal the general underlying structure which generates or allow
such a variation.

`Comparison is one of the most efficient methods for explicating or utilizing

tacit knowledge or tacit attitudes. This can be done, for example, by showing in parallel
two slides of two slightly different objects or situations and by asking people to explain
verbally their differences. In comparative study, we examine two or more cases,
specimens or events. But two main styles are as under;
i. Descriptive Comparison: Descriptive comparison aims at describing
and perhaps also explaining the invariance of the objects. It does not aim at
generating changes in the objects; on the contrary, it usually tries to avoid them.
ii. Normative Comparison: A special style of comparative study is
needed when the aim is not just to detect and explain but also to improve the
present state of the object or to help improving or developing similar object in
the future. This is the technique of normative comparison.

The Comparative approach has always existed in the social sciences ‐contrary to
the natural sciences, which think of themselves as universal in their approach‐but the
changes now taking place are opening up a new dimension for them and justify a
broader scope.

7
 Comparison, having been considered initially an original and interesting
approach with marginal status, is now beginning to be seen as an essential tool for
generating knowledge. The principle of comparability, whilst it forms part of any
comparative approach, comes in a variety of forms, however, according to the object of
the research. To transfer knowledge on best practices concerning, for instance, an
immigration integration policy is not the same as research to add to knowledge of the
functioning of the drug network or research on a new approach to gender relations.The
Comparative study involves a systemizedendeavor to compare two items with an eye
towardidentifying points that the items hold in common,along with citing areas where
the two items differ andcomparative study takes place in a number of
differentenvironments, and usually have a specific purpose inmind.At the root of the
research design of a comparativestudy is a rubric. Essentially a rubric is the set of
criteria that is used to evaluate each aspect of twoitems under comparison.

8
1.2. STATEMENT OF THE PROBLEM:
Some medicines had only power to make a postponement to diseases like
cancer, HIV, Asthma, Tuberculosis, etc. With this view they were more pharmaceutical
companies were involved in research for making new medicines for those diseases, in
India one of the leading two pharmaceutical companies like Cipla & Cadila were doing
better in this pandemic situation (COVID-19) too.
In terms of not only top companies caused diseases but also much common
illness like cough & cold, Fever, Head ache; Ulcers were cured by those company
medicines. So I conducted a comparative study towards the Cipla and Cadila for which
is best upon the common peoples and prescribed by doctors mostly.

9
1.3. OBJECTIVES OF THE STUDY:
1. To study the Pharmaceutical Industry and its operations in India,
2. To know the Pharmaceutics under the companies of Cipla & Cadila,
3. To compare the two Pharmaceutical companies such as Cipla & Cadila
by sales under Bombay Medicals,
4. To know the sales turnover between of Cipla & Cadila pharmaceutics
on Bombay Medicals,
5. To analyse the demographic factors of patients to chose between Cipla
& Cadila,
6. To analyse the discipline of doctors who prescribed the Cipla & Cadila
Pharmaceutics,
7. To summarize suggestions and conclusion in accordance of findings of
the study

1.4. SCOPE OF THE STUDY:

 The study helps to know the meaning of pharmaceuticals and how that
would play a vital role in our day to day life.
 The study helps to know the pharmaceutical companies which active in
India.
 To analyse and compare the two pharmaceutical companies like Cipla &
Cadila.
 To ensure which is better and which has a more impact on peoples in
accordance with their economic standards.
 To know the medicine preference of doctors between the Cipla & Cadila
medicines.

10
 1.5. INDUSTRY PROFILE

PHARMACEUTICAL INDUSTRY IN INDIA:

The pharmaceutical industry in India was valued at US$33 billion in 2017

and generic drugs account for 20 per cent of global exports in terms of volume, making
the country the largest provider of generic medicines globally. According to the
Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, domestic
pharmaceutical market turnover reached Rs 129,015 crore (US$18.12 billion) in 2018,
growing 9.4 per cent year-on-year and exports revenue was US$17.28 billion in FY18
and US$19.14 billion in FY19.

Hyderabad, Mumbai, Pune,(Baddi, HimachalPradesh), Chennai, Bangalore, Ah

medabad, Vadodara, Ankleshwar, Vapi, Sikkim and Kolkata are the major
pharmaceutical hubs of India. The Government started to encourage the growth of drug
manufacturing by Indian companies in the early 1960s, and with the Patents Act in
1970.

Indian companies carved a niche in both the Indian and world markets with
their expertise in reverse-engineering new processes for manufacturing drugs at low
costs which became the advantage for industry. India's biopharmaceutical industry
clocked a 17 percent growth with revenues of Rs. 137 billion ($1.8 billion) in the 2009-
10 financial year over the previous fiscal. Biopharma was the biggest contributor
generating 60 percent of the industry's growth at Rs. 8,829 crore, followed by bio-
services at Rs. 2,639 crore and bio-agri at Rs. 1,936 crore.

As of 2002, over 20,000 registered drug-manufacturers in India sold $9 billion

worth of formulations and bulk drugs. 85% of these formulations were sold in India
while over 60% of the bulk drugs were exported, mostly to the United States and to
Russia. Most of the players in the market are small-to-medium enterprises; 250 of the
largest companies control 70% of the Indian market. Thanks to the 1970 Patent Act,
multinationals represent only 35% of the market, down from 70% thirty years ago.

Most Pharma companies operating in India, even the multinationals, employ

Indians almost exclusively from the lowest ranks to high-level management.
Homegrown pharmaceuticals, like many other businesses in India, are often a mix of
public and private enterprise.

11
 In terms of the global market, India currently holds an accountable share and is
known as the pharmacy of the world and as the biggest generic supplier. India gained
its foothold on the global scene with its innovatively-engineered generic drugs and
active pharmaceutical ingredients (API), the country accounts for around 30 per cent
(by volume) and about 10 per cent (value) in the US$70–80 billion US generics market.
Growth in other fields notwithstanding generics is still a large part of the picture. India
is the largest provider of generic drugs globally. The Indian pharmaceutical-sector
industry supplies over 50 per cent of global demand for various vaccines, 40 per cent of
generic demand in the US and 25 per cent of all medicine in the UK. India is the largest
contributor in UNESC with over 50-60% share.

EXPORTS

Exports of pharmaceuticals products from India increased from US$6.23 billion

in 2006–07 to US$8.7 billion in 2008-09 a combined annual growth rate of 21.25%.

India exported $11.7 billion worth of pharmaceuticals in 2014. Pharmaceutical

export from India stood at US$17.27 billion in 2017–18, and is expected to grow by 30
per cent to reach US$20 billion by the year 2020.And India Share in This 40% The 10
countries below imported 56.5% of that total:
1 United States $3800 32.9%
2 South Africa $461.1 3.9%
3 Russia $447.9 3.8%
4 United Kingdom $444.9 3.8%
5 Nigeria $385.4 3.3%
6 Kenya $233.9 2%
7 Tanzania $225.2 1.9%
8 Brazil $212.7 1.8%
9 Australia $182.1 1.6%
10 Germany $178.8 1.5%

12
Top 10 listed pharmaceutical companies in India by market capitalization as of
June 2020.
Rank Company Market Capitalization June
2020 (INR crores)
1 Sun Pharmaceutical 116,415
2 Dr. Reddy's Laboratories 66,596
3 Divi's Laboratories 61,282
4 Cipla 51,645
5 Aurobindo Pharma 46,043
6 Torrent Pharmaceuticals 42,753
7 Lupin Ltd 41,747
8 Zydus Cadila 37,422
Healthcare
9 Abbott India 33,915
10 Alkem Laboratories 27,807

PRODUCT DEVELOPMENT:
Indian companies are also starting to adapt their product development processes
to the new environment. For years, firms have made their ways into the global market
by researching generic competitors to patented drugs and following up with litigation to
challenge the patent. This approach remains untouched by the new patent regime and
looks to increase in the future. However, those that can afford it have set their sights on
an even higher goal: new molecule discovery. Although the initial investment is huge,
companies are lured by the promise of hefty profit margins and thus a legitimate
competitor in the global industry. Local firms have slowly been investing more money
into their R&D programs or have formed alliances to tap into these opportunities.

13
 1.6. COMPANY

PROFILE

CADILA

Cadila Pharmaceuticals Ltd. is one of the largest privately-held pharmaceutical

companies in India. Over the past six decades, they have been developing and
manufacturing affordable medicines for patients around the world.

Their innovation-led drug discovery processes ensure the health and well-being
of people around the world. Their enhanced investment in innovation and a strong track
record in research and development have produced medical miracles that have changed
lives and made a profound impact on real life.

Being a care-focused, research-driven company, they are committed to

complying with the highest ethical standard in clinical research and medical practice.
They want to be valued not only for their pharmaceutical products but also for the way
they conduct our research and business activities.

They lead our industry in demonstrating the application of cutting-edge research

to ethical business practices in producing the alchemy of optimum health outcomes for
all.

14
VISION & MISSION STATEMENTS:

VISION
Their vision is to be a leading pharmaceutical company in India and to become
a significant global player by providing high quality, affordable and innovative
solutions in medicine and treatment.

MISSION
Their will discover, develop and successfully market pharmaceutical products to
prevent, diagnose, alleviate and cure diseases. They shall provide total customer
satisfaction and achieve leadership in chosen markets, products and services across the
globe, through excellence in technology, based on world-class research and
development.

They are responsible to the society. They shall be good corporate citizens and
will be driven by high ethical standards in their practices.

PRODUCTS AND SERVICES

Cadila Pharmaceuticals is the only Indian manufacturer of natural Streptokinase
and Hyaluronic Acid products. The company was also the first in the world to introduce
Rabeprazole in IV form – ‘Rabeloc’.[6] In 2009, the world’s first boosted-Rifampicin
fixed-dose combination for the treatment of Tuberculosis – ‘Risorine’ and world's first
drug combination for prevention of Cardiovascular Diseases – ‘Polycap’ were
introduced by Cadila Pharmaceuticals.[8] For the patients suffering from Non Small Cell
Lung Cancer (NSCLC), company has recently introduced ‘Mycidac-C’ - first in the
class active immunotherapy as well as drug targeting Desmocollin.[9] Some of the top
brands of the company are Aciloc, Envas, Calcirol, Haem Up, Vasograin, Tricort,
Fludac, Rabiloc, Trigan-D, Mycobutol and Sepsivac.

15
 CIPLA

Cipla Limited is an Indian multinational pharmaceutical company,

headquartered in Mumbai, India. Cipla primarily develops medicines to treat
respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression;
other medical conditions.
As of 17 September 2014, its market capitalization was Rs. 49,611.58
crore (equivalent to Rs.530 billion or US$7.5 billion in 2019), making it India's 42nd
largest publicly traded company by market value. On 23 April 2019, Cipla appointed
Dr. Raju Mistry as Global Chief People Officer.

It was founded by Khwaja Abdul Hamied as 'The Chemical, Industrial

& Pharmaceutical Laboratories' in 1935 in Mumbai. The name of the company was
changed to 'Cipla Limited' on 20 July 1984. In the year 1985, the US FDA approved the
company's bulk drug manufacturing facilities. Led by the founder's son Yusuf Hamied,
a Cambridge-educated chemist, the company provided generic AIDS and other drugs to
treat poor people in the developing world. In 1995, Cipla launched Defer prone, the
world's first oral iron chelator. In 2001, Cipla offered medicines (antiretroviral)
for HIV treatment at a fractional cost (less than $350 per year per patient).

In 2013 Cipla acquired the South African company Cipla-Medpro, kept it as a

subsidiary, and changed its name to Cipla Medpro South Africa Limited. At the time of
the acquisition Cipla-Medpro had been a distribution partner for Cipla and was South
Africa's third biggest pharmaceutical company. The company had been founded in
2002 and was known as Enaleni Pharmaceuticals Ltd. In 2005, Enaleni bought all the
shares of Cipla-Medpro, which had been a joint venture between Cipla and Medpro
Pharmaceuticals, a South African generics company, and in 2008 it changed its name to
Cipla-Medpro.

16
1.7. LIMITATIONS OF THE STUDY:
 The study was restricted to internal human resources of the company.
 The response from the employees may be biased.
 The sample size is limited to 120 respondents.
 The study was targeted towards opinions of mixed packages like employees,
doctors, pharmacy staffs, distributors, etc.
 The study has a time restriction of three months only.
 The present study only covers the common compatibilities between the cipla &
cadila pharmaceuticals.

17
1.8. CHAPTER SCHEME
Organization of the Report
Chapter I
This chapter deals with the Introduction of the Study which covers Introduction,
statement of the problem, objectives of the study, scope of the study, Industry
profile, Company Profile, Limitations of the study.
Chapter II
This Chapter deals with the Review of Literature, Research Gap.
Chapter III
This chapter deals with a Research Methodology of the study. It shows sampling,
period cover by the study, sources of data, tools used for the study, Hypothesis of
the study.
Chapter IV
This chapter deals with the Data Analysis and Interpretation, Testing of
hypothesis of the study.
Chapter V
This chapter deals with the Summary of Findings, Suggestions & Conclusion of
the Study.

18
 CHAPTER - II

2.1. REVIEW OF LITERATURE

Soham Samajpaty (2020), describes “A Comparative study of Covid-19

Vaccine technology”, the aim of this study to discuss in brief the major technical
approaches in vaccine development. Worldwide the vaccines which are being
developed are not completely successful. Mutations and novel mutations of COVID19
is a major hindrance to a permanent solution to this disastrous pandemic. Much more
detailed and cautious of vaccines is necessary. Noble purpose is as always a desired and
expected behavior. Companies should not see this as an opportunity of growth but
should come up with efficient research and novel technology and much more efficient
vaccines to end this era.

Sudipta Ghosh (2019) “A Comparative Study Between Power Generation

And Power Transmission Industries “study is an attempt to compare the liquidity
performance. between power generation and power transmission industries during the
period 2008-09 to 2017-18 the study reveal that in spite of unsatisfactory liquidity
performance in terms of current ratio of both the industries (i.e., power and
transmission), the true liquidity performance as measured by quick ratio of both the
industries in the Indian central power sector is found to be satisfactory.

Khyser Mohammad .al (2016) “A Comparative Study Between Colgate

Palmolive And Dabur India Limited”. The present article is an attempt made to
examine the financial performance of Colgate Palmolive and Dabur India Ltd which
were the leading brands in personal care segment of FMCG Sector in India over the
past few decades, India with a population more than one billion was the largest
economies in the world in terms of purchasing power and consumer spending next to
china and fourth largest sector in India. In the present study we had used the accounting
ratios and the statistical tools such as linear regression analysis and multiple correlation
analysis to determine the financial performance, Overall the financial performance of
the Dabur India ltd was good in comparison to Colgate Palmolive.

Bram Foubert .al (2018), “A Comparative Study of the Purchase Effects of

Premiums and Price Cuts” As an alternative to promotional price cuts, retailers and

19
manufacturers often rely on non-price promotion techniques, such as premium
promotions, where consumers receive a gift with the purchase of a product. They
compare the effectiveness of premiums to that of price cuts, and study moderators of
this comparative premium effectiveness. They use data from a large online shopping
simulation study with more than 2,000 participants to model consumers’ purchase
decisions in response to premiums and price cuts. Results indicate that the impact of
premiums on purchase behavior is systematically lower than that of equivalent price
cuts. However, a premium’s smaller sales impact may be off set by a cost advantage.
This is especially true for private label brands where the premium’s purchase effects do
not differ too much from those of a price cut. They calculate how large the cost
advantage has to be for a premium to be more profitable than a price cut, and show that
premiums entail risks as well as opportunities, for both manufacturers and retailers.

Patricia van Loon .al (2015), “A comparative analysis of carbon emissions

from online retailing of fast moving consumer goods”. Online retailing can lower the
environmental impact of shopping under specific circumstances. As a result of the
numerous variables involved, most of the studies that have compared the carbon
footprints of online and conventional retailing only take a partial view. To make a more
holistic assessment, this study develops a framework that accounts for all the relevant
environmental factors relating to retail/e-commerce activities. Variables related to
consumer shopping behaviour such as basket size, transport mode, trip length and trip
frequency are included in the analysis. This framework is used to build a Life Cycle
Analysis model. The model is applied to different online retail methods for fast-moving
consumer goods in the United Kingdom. they find that, within the “last mile” link to
the home, the nature of the consumer's behaviour in terms of travel, choice of e-
fulfilment method and basket size are critical factors in determining the environmental
sustainability of e-commerce. The nature and routing of van deliveries, the amount and
type of packaging used, and the energy efficiency of shop and e-fulfilment centre
operations are also identified as significant contributors to climate change potential.
The results of this study indicate ways in which e-commerce can be made more
environmentally sustainable, encouraging consumers to reduce complementary
shopping trips and maximise the number of items per delivery. This study identifies the
strengths and weaknesses of a range of e-retail channels and provides a basis for future
research on the environmental sustainability of online retailing of fast-moving

20
consumer goods.

21
2.2. RESEARCH GAP:
The comparative study of the reviews shows the relationship or differences or
similarities between the two entities which has the same impact or in same discipline.
Most of the comparative study between the two concerns was to be fit to each other.
But in this case, this study describes the unfit and competitive to each other belongs to
same country. The main research gap on the study describes the comparison between
two pharmaceutical companies in term of common factors like sales, preferences,
economically benefited, availability and the prescription etc. and the study was
specially reference to Bombay medicals situated at Aruppukottai Town district which
has widely cover the one fourth of the city.

22
 CHAPTER - III

3.1 RESEARCH METHODOLOGY

3.1.1 RESEARCH FRAMEWORK:

A research framework provides an underlying structure or model to support our

collective research efforts. A framework helps us to determine, based on what we’re
trying to learn, the right approach and methods to apply in a given situation. It also
helps to structure and plan our research activities, according to the breadth and scope of
what we’re trying to learn. This research has the descriptive study that is based upon the
comparative study on cipla and cadila with reference to employees at Bombay
Medicals., Aruppukottai Town city, Tamil Nadu state, India. The period of time for
conducting research is three month starting January to March 2021. The methodologies
for this study comprises of Descriptive research design with sampling, data collection
and data analysis.

3.2 SAMPLING:
3.2.1 DATA COLLECTION:

Questionnaire is used as an effective tool for data collection. The data getting
through questionnaire was framed and filled through Google forms. There were 120
Customers from whom the survey was collected.

3.2.2 PRIMARY DATA:

Primary data are those which are new and original in nature. These data are the
first hand information generated to achieve the purpose of the research. The primary
data for this research collected through Questionnaire.

3.2.3 SECONDARY DATA:

Secondary data are those data which are not new and original in nature. These
data are obtained from published and unpublished sources. For the purpose of
collection of data, various secondary sources were used. The secondary source used
includes different magazines, books, articles on websites like shodhganga, research
gate, were also used for gathering information.
23
3.3 PERIOD OF THE STUDY:
This study describes the comparative study between the Cipla & Cadila, the
survey on employees could conduct on one month basis. But this study duration is three
month.

3.4 SOURCES OF DATA:

The universe core for this study is based on Descriptive Research under
Qualitative Research Design, Which means getting data through descriptive form i.e.,
the experiences of the respondents.
Primary data collected through Google form from the respondent through
questionnaire method. The questionnaire was administered to 120 employees. The
secondary source used includes different magazines, books, articles on websites like
Shodh Ganga, research gate, were also used for gathering information.
3.5 TOOLS FOR ANALYSING DATA:
The data analysis and interpretation process helps to arrive at a solution to the
research problem. The data collected from the primary sources are proposed to be
analyzed using the SPSS appropriate statistical tool like Percentage analysis, Chi –
square, Correlation.
3.5.1 Percentage Analysis:
A percentage frequency distribution is a display of data that specifies the
percentage of observations that exist for each data point or grouping of data points. It is
a particularly useful method of expressing the relative frequency of survey responses
and other data.

𝑷𝒆𝒓𝒄𝒆𝒏𝒕𝒂𝒈𝒆 = 𝑵𝒐. 𝒐𝒇. 𝒓𝒆𝒔𝒑𝒐𝒏𝒅𝒆𝒏𝒕𝒔

× 𝟏𝟎𝟎
𝑻𝒐𝒕𝒂𝒍 𝑵𝒐. 𝒐𝒇.
3.5.2 Correlation 𝑹𝒆𝒔𝒑𝒐𝒏𝒅𝒆𝒏𝒕𝒔
analysis:

Correlation is a bivariate analysis that measures the strength of association

between two variables and the direction of the relationship. In terms of the strength of
relationship, the value of the correlation coefficient varies between +1 and -1. A value
of ± 1 indicates a perfect degree of association between the two variables. As the
correlation coefficient value goes towards 0, the relationship between the two variables
will be weaker. The direction of the relationship is indicated by the sign of the

24
coefficient; a + sign indicates a positive relationship and a – sign indicates a negative

25
relationship. Usually, in statistics, we measure four types of correlations: Pearson
correlation, Kendall rank correlation, Spearman correlation, and the Point-Biserial
correlation.

3.6. HYPOTHESIS OF THE STUDY:

 Relationship between discount given for cadila medicine and drugs and
advertisement is for cadila for sales promotion.

26
 CHAPTER - IV

4.1. DATA ANALYSIS &

INTERPRETATION Table 4.1.1: AGE OF

THE RESPONDENTS

Age No.of.Respondents Percentage

26 - 35 years 31 25.8%
36 - 45 years 13 10.8%
Above 45 years 5 4.2%
Below 25 years 71 59.2%
Grand Total 120 100%

Chart 4.1.1: AGE OF THE RESPONDENTS

Source: Primary Data

Analysis: From the survey data it is observed that 25.8% were between the 26 – 35
year group and 10.8% were 36 – 45 year group and 4.2% were Above 45 year’s group
and followed 59.2% respondents were below 25 years group.
Interpretation: It shows that the 59.2% of the respondents were below 25 years.

27
 Table 4.1.2: GENDER OF THE RESPONDENTS

Gender No.of.Respondents Percentage

Male 82 68.3%
Female 38 31.7%
Grand Total 120 100%

Chart 4.1.2: GENDER OF THE RESPONDENTS

Source: Primary Data

Analysis: From the survey data it is observed that 68.3% of the male and followed
31.7% respondents are female.
Interpretation: It shows that 68.3% of the male and followed 31.7% respondents are
female.

28
 Table 4.1.3: LOCALITY OF THE RESPONDENTS

Locality No.of.Respondents Percentage

Urban 48 40%
Rural 60 50%
Semi-Urban 12 10%
Grand Total 120 100%

Chart 4.1.3: LOCALITY OF THE RESPONDENTS

Source: Primary Data

Analysis: From the survey data it is observed that 40% were from urban and 50% were
from Rural and followed 10% respondents were Semi-urban.
Interpretation: It shows that 50% of the respondents were from rural background.

29
 Table 4.1.4: MARITAL STATUS OF THE RESPONDENTS

Marital Status No.of.Respondents Percentage

Married 53 44.2%
Unmarried 61 50.8%
Widow 6 5%
Others 0 0%
Grand Total 120 100%

Chart 4.1.4: MARITAL STATUS OF THE RESPONDENTS

Source: Primary Data

Analysis: From the survey data it is observed that 44.2% were married and 50.8% were
Unmarried and 5% were widow and followed 0% respondents were others.
Interpretation: It shows that 50.8% of the respondents were Unmarried.

30
 Table 4.1.5: DISEASE RAPIDLY CURED BY CIPLA

Diseases No.of.Respondents Percentage

Blood pressure 10 8.3%
Cold 33 27.5%
Diabetics 5 4.2%
Fever 17 14.2%
Pain 45 37.5%
Ulcer 10 8.3%
Grand Total 120 100%

Chart 4.1.5: DISEASE RAPIDLY CURED BY CIPLA

Source: Primary Data

Analysis: From the survey data it is observed that 8.3% said blood pressure and 27.5%
said cold and 4.2% said Diabetics and 14.2% said fever and 37.5% said pain and
followed 8.32% respondents were said ulcer diseases cured rapidly by Cipla medicines
& Drugs.
Interpretation: It shows that 38% respondents believe that cipla cured Pains rapidly.

31
 Table 4.1.6: DISEASE RAPIDLY CURED BY CADILA

Diseases No.of.Respondents Percentage

Blood pressure 9 7.5%
Cold 38 31.7%
Diabetics 8 6.7%
Fever 16 13.3%
Pain 33 27.5%
Ulcer 16 13.3%
Grand Total 120 100%

Chart 4.1.6: DISEASE RAPIDLY CURED BY CADILA

Source: Primary Data

Analysis: From the survey data it is observed that 7.5% said blood pressure and 31.7%
said cold and 6.7% said Diabetics and 13.3% said fever and 27.5% said pain and
followed 13.3% respondents were said ulcer diseases cured rapidly by Cadila
medicines & Drugs.
Interpretation: It shows that 32% of the respondents said that Cadila cured cold rapidly.

32
 Table 4.1.7: AVAILABILITY OF CIPLA MEDICINE & DRUGS

Locality No.of.Respondents Percentage

Home town district 74 61.7%
Outer district 30 25%
Outer state 16 13.3%
Grand Total 120 100%

Chart 4.1.7: AVAILABILITY OF CIPLA MEDICINE & DRUGS

Source: Primary Data

Analysis: From the survey data it is observed that 61.7% said home town district and
25% said Outer district and followed 13.3% respondents were said outer state
availability of Cipla medicines & Drugs.
Interpretation: It shows that for 62% of the respondents’ cipla were available at home
town district areas.

33
 Table 4.1.8: AVAILABILITY OF CADILA MEDICINE & DRUGS

Locality No.of.Respondents Percentage

Home town district 75 62.5%
Outer district 34 28.3%
Outer state 11 9.2%
Grand Total 120 100%

Chart 4.1.8: AVAILABILITY OF CADILA MEDICINE & DRUGS

Source: Primary Data

Analysis: From the survey data it is observed that 62.5% said home town district and
28.3% said Outer district and followed 9.2% respondents were said outer state
availability of Cadila medicines & Drugs.
Interpretation It shows that for 63% of the respondents’ cadila were available at home
town district areas.
.

34
 Table 4.1.9: BOUGHT MEDICINES ON ONLINE

Nominal No.of.Respondents Percentage

Yes 32 26.7%
No 72 60%
Often 16 13.3%
Grand Total 120 100%

Chart 4.1.9: BOUGHT MEDICINES ON ONLINE

Source: Primary Data

Analysis: From the survey data it is observed that 26.7% said yes and 60% said no and
followed 13.3% respondents were said often for bought medicines of Cipla & Cadila.
Interpretation: It shows that 60% of the respondents never purchased Cipla and cadila
medicines through online.

35
 Table 4.1.10: PEOPLES / PATIENTS MOSTLY USE CIPLA
MEDICINES

Age Interval No.of.Respondents Percentage

Below 10 Yrs 32 26.7%
10 to 15 Yrs 20 16.7%
15 to 20 Yrs 27 22.5%
20 to 30 Yrs 21 17.5%
Above 30 Yrs 20 16.7%
Grand Total 120 100%

Chart 4.1.10: PEOPLES / PATIENTS MOSTLY USE CIPLA

MEDICINES

Source: Primary Data

Analysis: From the survey data it is observed that 26.7% were below 10 years of age
and 16.7% were 10 – 15 years of age and 22.5% were 15 – 20 years of age and 17.5%
were 20 – 30 years of age and 16.7% were Above 30 years of age respondents were
mostly used the cipla medicines.
Interpretation: It shows that the 32 respondents were below the age of 10 years of
Peoples / Patients used cipla medicines.

36
 Table 4.1.11: PEOPLES / PATIENTS MOSTLY USE CADILA
MEDICINES

Age Interval No.of.Respondents Percentage

Below 10 Yrs 20 16.7%
10 to 15 Yrs 24 20%
15 to 20 Yrs 25 20.8%
20 to 30 Yrs 32 26.7%
Above 30 Yrs 19 15.8%
Grand Total 120 100%

Chart 4.1.11: PEOPLES / PATIENTS MOSTLY USE CADILA

MEDICINES

Source: Primary Data

Analysis: From the survey data it is observed that 16.7% were below 10 years of age
and 20% were 10 – 15 years of age and 20.8% were 15 – 20 years of age and 26.7%
were 20
– 30 years of age and 15.8% were Above 30 years of age respondents were mostly
used the cadila medicines.
Interpretation: It shows that the 32 respondents were below the age of 10 years of
Peoples / Patients used cadila medicines.
37
 Table 4.1.12: BRNAD SUGGESTED BY MD, DM DOCTORS
MOSTLY

Companies No.of.Respondents Percentage

Cipla 63 52.5%
Cadila 57 47.5%
Grand Total 120 100%

Chart 4.1.12: BRAND SUGGESTED BY MD, DM DOCTORS

MOSTLY

Source: Primary Data

Analysis: From the survey data it is observed that 52.5% doctors of MD, DM were
suggested Cipla medicines & drugs and followed 47.5% respondents said doctors of
MD,MD doctors were suggested cadila medicines & drugs.
Interpretation: It shows that 52.5% of the respondents suggested cipla medicines and
drugs who were MD, DM

38
 Table 4.1.13: BRNAD SUGGESTED BY MBBS DOCTORS
MOSTLY

Companies No.of.Respondents Percentage

Cipla 80 66.7%
Cadila 40 33.3%
Grand Total 120 100%

Chart 4.1.13: BRNAD SUGGESTED BY MBBS DOCTORS

MOSTLY

Source: Primary Data

Analysis: From the survey data it is observed that 66.7% doctors of MBBS were
suggested Cipla medicines & drugs and followed 33.3% respondents said doctors of
MBBS doctors were suggested cadila medicines & drugs.
Interpretation: It shows that 67% of the respondents suggested cipla medicines and
drugs who were MBBS

39
 Table 4.1.14: BRNAD SUGGESTED BY MBBS DLO DOCTORS
MOSTLY

Companies No.of.Respondents Percentage

Cipla 80 66.7%
Cadila 40 33.3%
Grand Total 120 100%

Chart 4.1.14: BRNAD SUGGESTED BY MBBS DLO DOCTORS

MOSTLY

Source: Primary Data

Analysis: From the survey data it is observed that 66.7% doctors of MBBS DLO were
suggested Cipla medicines & drugs and followed 33.3% respondents said doctors of
MBBS DLO doctors were suggested cadila medicines & drugs.
Interpretation: It shows that 66.7% of the respondents suggested cipla medicines and
drugs who were MBBS DLO

40
 Table 4.1.15: DISCOUNT FROM DISTRIBUTORS GIVES FOR
CIPLA MEDICINES & DRUGS

Discount Interval No.of.Respondents Percentage

20 -25 % 36 30%
Below 20% 52 43.3%
25 – 30% 17 14.2%
Above 30% 15 12.5%
Grand Total 120 100%

Chart 4.1.15: DISCOUNT FROM DISTRIBUTORS GIVEN FOR

CIPLA MEDICINES & DRUGS

Source: Primary Data

Analysis: From the survey data it is observed that 30% of respondents get 20 – 25%
and 43.3% of respondents get below 20% and 14.2% of respondents get 25 – 30% and
12.5% get above 30% of discounts from distributors of cipla medicines & drugs.
Interpretation: It shows that 43% of the respondent get 20% discount for Cipla.

41
 Table 4.1.16: DISCOUNT FROM DISTRIBUTORS GIVES FOR
CADILA MEDICINES & DRUGS

Discount Interval No.of.Respondents Percentage

20 -25 % 41 34.2%
Below 20% 46 38.3%
25 – 30% 21 17.5%
Above 30% 12 10%
Grand Total 120 100%

Chart 4.1.16: DISCOUNT FROM DISTRIBUTORS GIVES FOR

CADILA MEDICINES & DRUGS

Source: Primary Data

Analysis: From the survey data it is observed that 34.2% of respondents get 20 – 25%
and 38.3% of respondents get below 20% and 17.5% of respondents get 25 – 30% and
10% get above 30% of discounts from distributors of cadila medicines & drugs.
Interpretation: It shows that 38% of the respondent get 20% discount for Cadila.

42
 Table 4.1.17: ADVERTISEMENT IS FOR CADILA FOR SALES
PROMOTION

Nominal No.of.Respondents Percentage

Yes 55 45.8%
No 65 54.2%
Grand Total 120 100%

Chart 4.1.17: ADVERTISEMENT IS FOR CADILA FOR SALES

PROMOTION

Source: Primary Data

Analysis: From the survey data it is observed that 45.8% said yes and followed 54.2%
respondents said no for advertisement of cadila medicines & drugs.
Interpretation: It shows that 54% of the respondents said no advertisement of cadila
medicines & drugs is given.

43
 Table 4.1.18: ADVERTISEMENT IS FOR CIPLA FOR SALES
PROMOTION

Nominal No.of.Respondents Percentage

Yes 56 46.7%
No 64 53.3%
Grand Total 120 100%

Chart 4.1.18: ADVERTISEMENT IS FOR CIPLA FOR SALES

PROMOTION

Source: Primary Data

Analysis: From the survey data it is observed that 46.7% said yes and followed 53.3%
respondents said no for advertisement of cipla medicines & drugs.
Interpretation It shows that 53% of the respondents said no advertisement of cadila
medicines & drugs is given.

44
Table 4.1.19: NOMINAL LEVEL FOR COMPARISON OF CIPLA &
CADILA

Sl.No Statements Cipla Cadila TOTAL

1. High sales 77 43 120

Percentage 64.2% 35.8 100%
2. The rapid pain killer 66 54 120
from
Percentage 55% 45% 100%
3. Doctors suggest most 74 46 120
for general health
issues?
Percentage 61.7% 38.3% 100%
4. Which company best 70 50 120
suits for cough and
cold
Percentage 58.3% 41.7% 100%
5. Adorable price for 74 46 120
middle class family.
Percentage 61.7% 38.3% 100%
6. Produces more its 68 52 120
medicine as pills
Percentage 56.7% 43.3% 100%
7. Produces more its 78 42 120
medicine as syrups
Percentage 65% 35% 100%
8. Produces more its 61 59 120
medicine as gel /
cream
Percentage 50.8% 49.2% 100%

45
Chart 4.1.19: NOMINAL LEVEL FOR COMPARISON OF CIPLA &
CADILA

Source: Primary Data

Analysis:
 From the survey data it is observed that 64.2% cipla and 35.8% cadila is
yielding high sales.
 From the survey data it is observed that for 55% of the respondents’ cipla and
45% of the respondents cadila is a rapid pain killer.
 From the survey data it is observed that for 61.7% cipla and 38.3% cadila
doctors suggested most for general health issues.
 From the survey data it is observed that 58.3% of cipla and 41.7% of cadila suits

46
 for best on cough & cold.
 From the survey data it is observed that 61.7% of cipla and 38.3% of cadila was
at affordable price on middle class families.
 From the survey data it is observed that 56.7% of cipla and 43.3% of cadila
were producing more pills as medicines.
 From the survey data it is observed that 65% of cipla and 35% of cadila was
used for producing more syrup as medicines.
 From the survey data it is observed that 50.8% of cipla 49.2% of cadila was
used for producing more gel / cream as medicines.

47
 Table 4.1.20: DOCTORS DISCIPLINES WHO SUGGESTS CIPLA
MOSTLY

Doctors Disciplines No.of.Respondents Percentage%

Gynecologists 56 46.7%
Neurologist 47 39.2%
Orthopedists 48 40%
Urologists 40 33.3%
ENT Specialist 32 26.7%
Pediatricians 31 25.8%
Ophthalmologists 33 27.5%

Chart 4.1.20: DOCTORS DISCIPLINES WHO SUGGESTED CIPLA

MOSTLY

Source: Primary Data

Analysis:
From the survey data it is observed that 46.7% said ophthalmologist& 39.2% said
Neurologists & 40% said Orthopedists& 33.3% said Urologists & 26.7% said ENT
specialist & 25.8% said Pediatricians& 27.5% said Ophthalmologists.
Interpretation: It shows that the 56% of the Gynecologists suggested cipla Medicines.

48
Table 4.1.21: DOCTORS DISCIPLINES WHO SUGGESTS CADILA
MOSTLY

Doctors Disciplines No.of.Respondents Percentage%

Gynecologists 36 30%
Neurologist 24 20%
Orthopedists 41 34.2%
Urologists 34 28.3%
ENT Specialist 42 35%
Pediatricians 48 40%
Ophthalmologists 50 41.7%

Chart 4.1.21: DOCTORS DISCIPLINES WHO SUGGESTS CADILA

MOSTLY

Source: Primary Data

Analysis:
From the survey data it is observed that 30% said ophthalmologist & 20% said
Neurologists & 34.2% said Orthopedists& 28.3% said Urologists &35% said ENT
specialist & 40% said Pediatricians & 41.7% said Ophthalmologists.
Interpretation: It shows that the 50% of the Gynecologists suggested cadila Medicines.

49
 4.2. TESTING OF HYPOTHESIS:
CORRELATION

Null hypothesis (Ho):

There is a relationship between discount given for cadila medicine and

drugs and advertisement is for cadila for sales promotion.

Alternate hypothesis (H1):

There is no relationship between discount given for cadila medicine and drugs and
advertisement is for cadila for sales promotion.

Correlations
Discount Advertisement
Discount Pearson Correlation 1 .748**
Sig. (2-tailed) .000
N 120 120
Advertisement Pearson Correlation .748** 1
Sig. (2-tailed) .000
N 120 120
**. Correlation is significant at the 0.01 level (2-tailed).

Since the significance value 0.01 which is less than 0.05 Therefore there is a
positive correlation relationship between discount given for cadila medicine and drugs
and advertisement is for cadila.
Hence, the Null hypothesis [Ho] is accepted

INFERENCE:

There is positive correlation relationship between discount given for cadila medicine
and drugs and advertisement is for cadila for sales promotion.

50
 CHAPTER – V
5.1. FINDINGS
 59.2% of the employees were below 25 years,
 68.3% of the male and followed 31.7% respondents are female,
 50% of the employees were from rural background,
 50.8% of the employees were Unmarried,
 38% of respondents believe that cipla cured pains rapidly,
 32% of respondents said that the cadila cured cold rapidly,
 62% of respondents said cipla were available at home town district areas.
 63% of respondents said cadila were available at home town district areas.
 60% of respondents said they never purchased cipla & cadila medicines through
online,
 32 respondents were below the age of 10 years of people / patients used cipla
medicines,
 32 respondents were below the age of 10 years of people / patients used cadila
medicines,
 52.5% of respondents suggested cipla medicines & drugs who were MD, DM,
 67% of respondents suggested cipla medicines and drugs who were MBBS,
 66.7% of respondents suggested cipla medicines & drugs who were MBBS DLO,
 43% of respondents get 20% discount for cipla,
 38% of respondents get 20% discount for cadila,
 54% of the respondents said no advertisement of cadila medicines & drugs,
 53% of the respondents said no advertisement of cipla medicines & drugs,
 From the survey data it is observed that 64.2% cipla and 35.8% cadila is
yielding high sales.
 From the survey data it is observed that for 55% of the respondents’ cipla and
45% of the respondents cadila is a rapid pain killer.
 From the survey data it is observed that for 61.7% cipla and 38.3% cadila
doctors suggested most for general health issues.
 From the survey data it is observed that 58.3% of cipla and 41.7% of cadila
suits for best on cough & cold.
 From the survey data it is observed that 61.7% of cipla and 38.3% of cadila was
at affordable price on middle class families.

51
 From the survey data it is observed that 56.7% of cipla and 43.3% of cadila
were producing more pills as medicines.
 From the survey data it is observed that 65% of cipla and 35% of cadila was
used for producing more syrup as medicines.
 From the survey data it is observed that 50.8% of cipla 49.2% of cadila was
used for producing more gel / cream as medicines.
 56% of the gynecologist suggested cipla medicines,
 50% of the gynecologist suggested cadila medicines.
 There is positive correlation relationship between discount given for cadila
medicine and drugs and advertisement is for cadila for sales promotion.

52
 5.2. SUGGESTIONS
 The cipla and cadila are the one of the leading pharmaceuticals manufacturing and
distributing all over the world economy.
 The cipla should focus only on certain human issues which was nor controlled and
eradicated by such decades, so the company may focuses the common illness of a
common man,
 Cadila gives a wonderful pharmaceuticals and made a economical tieup with other
countries and collaborates with more foreign pharmaceutical industries, but they
had also a certain focus in inland issues.
 Many of the chief specialisy of certain disciplines mostly suggest or prescribed
cipla medicines and drugs, because some of them were said it’s suits to our tropical
regional health issues more than cadila.
 But in surgical terminologist were said cadila gives a better rapid curing than other
medicines in the pharmaceutical industry.
 In COVID situation, we were not made similarities between any of the
pharmaceutical products, but in term, if we made a compatibility test we get more
anonymous results about those medicines and drugs.

53
 5.3. CONCLUSION
On conclude, any organisation needs to improve their productivity on optimum
level, they can achieve it by the vision & mission statements clearly and also they can
enhance their factors of internal & external effectively. The both factors are considered
significantly and the factors are inter - connected or relationship with one another based
upon the nature of the organisation. The customer satisfaction through the trend value is
a predominant factor for any organization to meet its framed objectives. By this study
we could understand how, when, where it could affects and the associations and
comparisons between the cipla and cadila medicines and drugs with the special
reference to Bombay medical at Aruppukottai Town district. The compatibility of those
companies were more or less gives a closer results among the pharmacy employees,
distributors, doctors of various diciplines, etc.

54
 ANNEXURE

QUESTIONNAIRE

Dear Sir / Madam,

Myself R.Praveen Kumar, student of BBA, Department of Business

Administration, Devangar Arts College, Aruppukottai Town. I conduct a survey on “A
COMPARATIVE STUDY ON CIPLA AND CADILA PHARMACEUTICALS
WITH REFERENCE TO BOMBAY MEDICALS, ARUPPUKOTTAI TOWN” and
have designed this questionnaire to collect data from the employees of the concern. The data
collected will be used and reported in aggregate form; no individual responses will be referred
to or quoted. The information you furnish will be treated as confidential. You are requested to
take 5 minutes out of your busy schedule to fill this survey. Your cooperation is highly
appreciated and thank full.

1. Age

(a) Below 25 Years (b) 26 - 35 Years

(c) 36 - 45 Years (d) Above 45 Years
2. Gender:
(a) Male (b) Female
3. Locality:
(a) Urban (b) Rural (c) Semi - Urban
4. Marital Status:
(a) Married (b) Unmarried (c) Widow (d) Other
5. Which of the following disease was rapidly cured by cipla?
(a) cold (b) pain (c) blood pressure
(d) fever (e) ulcer (f) diabetics

6. Which of the following diseases was rapidly cured by cadila?

(a) cold (b) pain (c) blood pressure
(d) fever (e) ulcer (f) diabetics

7. Where do you buy cipla medicine &drugs?

(a) Home town district (b) outer district (c) outer state

55
8. Where do you buy cadila medicine & drugs?
(a) Home town district (b) outer district (c) outer state

9. Are you bought your medicine bought online?

(a) Yes (b) No

10. For how many years the cipla medicines has benefitted you?
(a) below 10 yrs (b) 10 to 15 yrs (c) 15 to 20 yrs (d) 20 to 30 yrs
(e) Above 30 yrs
11. For how many years the cadila medicines has benefitted medicines?
(a) below 10 yrs (b) 10 to 15 yrs (c) 15 to 20 yrs (d) 20 to 30 yrs
(e) Above 30 yrs

12. Which brand was suggested by MD, DM Doctors the most?

(a) cipla (b) cadila

13. Which company was suggested by MBBS mostly?

(a) cipla (b) cadila

14. Which company was suggested by MBBS DLO mostly?

(a) cipla (b) cadila

15. How much discount from distributors gives for cipla medicines&
drugs? (a) 20 –25% (b) below 20% (c) 25 - 30%
(d) Above 30%

16. How much discount from distributors gives for cadila medicines& drugs?
(a) 20 – 25% (b) below 20% (c) 25 - 30% (d) Above 30%

17. Is any advertisement is for cadila for sales promotion? (a) Yes (b) No

18. Is any advertisement is cipla for sales promotion? (a) Yes (b) No

19. The following are the statements, which indicate the level of comparativeness
between the Cipla & Cadila.

Sl.No Statements Cipla Cadila

1. High sales

56
 2. The rapid pain killer from

3. Doctors suggest most for

general health issues.
4. Which company best suits for
cough and cold
5. Adorable price for middle
class family.
6. Produces more its medicine as
pills
7. Produces more its medicine as
syrups
8. Produces more its medicine as
gel / cream

20. Which discipline of doctors mostly suggests the cipla medicines and drugs?
(a)Gynaecologists (b) Neurologists (c) Orthopaedists
(d) Urologists (e) ENT Specialists (f) Podiatrists
(g) Ophthalmologist

21. Which discipline of doctors mostly suggests the cadila medicines and
drugs? (a)Gynaecologists (b) Neurologists (c) Orthopaedists
(d) Urologists (e) ENT Specialists (f) Podiatrists
(g) Ophthalmologist

57
 REFERENCES
BIBLIOGRAPHY
1. Soham Samajpaty (2020) “A Comparative study of Covid-19 Vaccine
technology”
2. Sudipta Ghosh (2019) “A Comparative Study Between Power Generation and
Power Transmission Industries “
3. S. M. Shariq Abbas (2017) “A Comparative Study of Women Employees on Job
Satisfaction: Reflections from Banks and FMCG Companies”
4. Swati Anand (2019 “A Comparative Study of Emotional Intelligence of Private
and Public Sector Bank Employees of Dehradun District”
5. Sudipta Ghosh (2019) “A Comparative Study Between Power Generation And
Power Transmission Industries”
6. B. Lalitha Subhanam (2019) “A Comparative Study Of Public & Private Life
Insurance Companies In India”
7. Mohd Taqi (2018) “A Comparative Study of Punjab National Bank and HDFC
Bank”
8. Devika K R (2019) “A Study on Comparative Analysis between Mutual Funds
and Equity Shares”, at ICICI Direct Securities Limited, Bangalore”.
9. Pooja Puri.al (2017),“A Comparative Study of LIC and Private Insurance
Companies
10. A. Palanisamy (2016) “A Comparative Study on Working Capital Management
of Selected Pharmaceutical Companies in India”.
11. Khyser Mohammad (2016) “A Comparative Study Between Colgate Palmolive
And Dabur India Limited”
12. Bram Foubert, Els Breugelmans, Karen Gedenk, Charlotte Rolef,
13. Something Free or Something Off? A Comparative Study of the Purchase
Effects of Premiums and Price Cuts, Journal of Retailing, Volume 94, Issue 1,
2018, Pages 5-20, ISSN 0022-4359.
14. Patricia van Loon, Lieven Deketele, Joost Dewaele, Alan McKinnon, Christine
Rutherford, A comparative analysis of carbon emissions from online retailing of
fast moving consumer goods, Journal of Cleaner Production, Volume 106, 2015,
Pages 478-486, ISSN 0959-6526.

58
WEBLIOGRAPHY:
 www.shodhganga.com
 www.researchgate.com
 www.sciencedirect.com
 www.yourarticlelibrary.com
 www.investopedia.com
 www.wikipedia.com
 www.cipla.com
 www.cadilapharma.com

59